Page 1 Extracted Terms:
- ACC/AHA (American College of Cardiology / American Heart Association)  
- Peripheral artery disease (PAD)  
- Cardiovascular disease  
- Heart disease  
- AHA Scientific Statements  
- Clinical performance measures  
- Performance measures  
- Quality indicators  
- Quality measures  
- Joint Committee on Performance Measures  
- Cardiovascular Angiography  
- Interventional Radiology  
- Cardiovascular and Pulmonary Rehabilitation  
- Vascular Medicine  
- Vascular Nursing  
- Vascular Surgery  
- Association of Black Cardiologists  
- American College of Cardiology (ACC)  
- American Heart Association (AHA)  
- Evidence‑based care  
- Medication management for PAD  
- Diagnostic testing for PAD  
- Treatment decisions  
- Follow‑up assessment  
- Patient‑centered care

Page 2 Extracted Terms:
**Key terms related to heart disease (primarily peripheral artery disease)**  

- Peripheral Artery Disease (PAD)  
- Lower‑extremity peripheral artery disease  
- Chronic limb‑threatening ischemia (CLTI)  
- Blood pressure management / Target BP for PAD (PM‑1)  
- Use of ACE inhibitors or ARBs for PAD (PM‑2)  
- Diabetes management in PAD (PM‑3)  
- Antithrombotic therapy for symptomatic PAD (PM‑4)  
- Lipid‑lowering therapy for PAD (high‑intensity statins) (PM‑5)  
- Novel lipid‑lowering drugs for PAD (QM‑4)  
- Tobacco use screening and counseling (PM‑6)  
- Structured exercise / community‑based exercise therapy (PM‑7)  
- Vascular review of systems for lower‑extremity PAD (QM‑1)  
- Pulse examination for PAD “at risk” patients (QM‑2)  
- Preventive foot care for PAD (QM‑3)  
- Identification of health disparities in PAD (QM‑5)  
- Saphenous vein assessment before leg revascularization (QM‑6)  
- Lower‑extremity surveillance after revascularization (QM‑7)  
- Multidisciplinary team evaluation for CLTI patients (QM‑8)  
- ACC/AHA peripheral artery disease guidelines  
- Class I (strong) recommendations  
- Public reporting of performance measures  
- Pay‑for‑performance (P4P) programs  
- Performance measures (PM‑1 to PM‑7)  
- Quality measures (QM‑1 to QM‑8)

Page 3 Extracted Terms:
- Peripheral Artery Disease (PAD)  
- Lower Extremity Peripheral Artery Disease  
- Atherosclerosis (peripheral arteries)  
- Claudication  
- Exertional leg disorders  
- Acute Limb Ischemia  
- Chronic Limb‑Threatening Ischemia  
- Cardiovascular Care  
- Cardiovascular Services  
- Performance Measures  
- Quality Measures  
- American College of Cardiology (ACC)  
- American Heart Association (AHA)  
- ACC/AHA Clinical Practice Guidelines  
- Class 1 Recommendations (Strong)  
- Class 2 Recommendations (Moderate)  
- Class 3 Recommendations (No benefit)  
- Level of Evidence (e.g., Class 1, 2, 3)  
- Performance Attribution  
- Pay‑for‑Performance Programs  
- Public Reporting  
- Multidisciplinary Care Team  
- Patient‑Centeredness  
- Timeliness, Safety, Effectiveness, Efficiency, Equity (quality domains)

Page 4 Extracted Terms:
- Peripheral Artery Disease  
- American College of Cardiology (ACC)  
- American Heart Association (AHA)  
- Class of Recommendation  
- Level of Evidence  
- Clinical Strategies  
- Interventions  
- Treatments  
- Diagnostic Testing  

Page 5 Extracted Terms:
**Key heart‑disease–related terms**

- ACC (American College of Cardiology)  
- AHA (American Heart Association)  
- ACE (Angiotensin‑Converting Enzyme)  
- ACE inhibitors  
- ARB (Angiotensin‑Receptor Blocker)  
- Blood pressure – BP  
- Peripheral artery disease – PAD  
- Chronic limb‑threatening ischemia – CLTI  
- Lipid‑lowering therapy (high‑intensity statins)  
- Statins  
- Antithrombotic therapy  
- Supervised exercise therapy – SET  
- Structured community‑based exercise therapy  
- Tobacco use screening and counseling  
- Diabetes management (in PAD)  
- Preventive foot care (in PAD)  
- Vascular review of systems (for PAD)  
- PAD “At‑Risk” pulse examination  
- Novel lipid‑lowering drugs (for PAD)  
- Saphenous vein assessment before leg revascularization  
- Lower extremity surveillance after revascularization  
- Multidisciplinary team evaluation (for CLTI)  
- Cost‑effectiveness evaluation  
- Guideline recommendations (Class 1, Class 2)  
- Performance measure (PM)  
- Quality measure (QM)

Page 6 Extracted Terms:
- Peripheral Artery Disease (PAD)  
- Lower‑extremity PAD  
- Atherosclerosis  
- Aortic disease  
- Major arterial branches  
- Catheter‑based treatment  
- Amputation risk  
- Preventive medical therapy  
- Risk‑factor modification  
- Smoking cessation  
- Procedural aspects of PAD care  
- Vascular medicine  
- Vascular nursing  
- Vascular surgery  
- Interventional radiology  
- Vascular and Endovascular Surgery Society (VESS)  
- Cardiovascular rehabilitation  
- High blood pressure (Hypertension)  
- ACC/AHA guideline for PAD management  
- AHA/ACC performance measures for adults with PAD  
- AHA/ACC guideline on lower‑extremity PAD  
- ACCF/AHA/ACR/SCAI performance measures for PAD  
- Cardiovascular disease (general term)

Page 7 Extracted Terms:
- Peripheral Artery Disease (PAD)  
- ACC/AHA Peripheral Artery Disease Measure Set  
- ACCF/AHA Peripheral Artery Disease performance measures  
- Performance measures (class I recommendations)  
- Quality measures (clinical practice guideline‑based)  
- Evidence‑based medicine  
- Clinical practice guidelines  
- Class I recommendation  
- Patient outcomes  
- Structural measures  
- Process measures  
- Outcome measures  
- High‑impact area (improving patient outcomes)  
- Care setting (inpatient, outpatient)  
- Measurement attributes (evidence‑based, reliability, validity, feasibility)  
- Gap in care  
- American College of Cardiology (ACC)  
- American Heart Association (AHA)

Page 8 Extracted Terms:
**Key terms related to heart disease (from the provided text)**  

- Peripheral Artery Disease (PAD)  
- Blood pressure medications  
- Diabetes care  
- Antithrombotic therapies  
- Lipid‑lowering therapy  
- Statin therapy (high‑intensity statin)  
- LDL‑C (low‑density lipoprotein cholesterol)  
- Cholesterol‑lowering medications  
- Smoking cessation / tobacco use  
- Supervised exercise  
- Community‑based exercise therapy  
- Lower extremity vein bypass graft surveillance  
- Vascular review of systems for lower extremity PAD  
- PAD “At Risk” population pulse examination  
- Wound care  
- Vascular testing interventions  
- Smartphone‑based tools leveraging artificial intelligence  
- AI‑powered imaging analysis for early PAD detection  
- Wearable sensors for PAD‑related physiologic changes  
- Health care access & treatment adherence  
- Health services research  
- Implementation science  
- Social determinants of health  
- Health disparities affecting PAD care  
- Continuous real‑time monitoring of disease progression  
- Clinical trial evidence for medical therapies  
- Post‑procedure combination therapies  
- Novel agents for diabetes, obesity, and hyperlipidemia  
- Risk amplifiers for PAD (guideline‑defined)  
- Cardiovascular outcomes & limb‑related events  
- Patient‑centered treatments  
- Cost‑effective medical management strategies.

Page 9 Extracted Terms:
- Peripheral Artery Disease (PAD)  
- Chronic Limb‑Threatening Ischemia (CLTI)  
- Major Adverse Cardiovascular Events (MACE)  
- Major Adverse Limb Events (MALE)  
- Angiotensin‑Converting Enzyme Inhibitors (ACEi)  
- Angiotensin‑Receptor Blockers (ARB)  
- Blood Pressure (BP)  
- Glucagon‑Like Peptide‑1 (GLP‑1) Agonists  
- Sodium‑Glucose Cotransporter‑2 (SGLT‑2) Inhibitors  
- Lipid‑Lowering Therapy  
- Statins (High‑Intensity Statins)  
- PCSK9 Inhibitors  
- Ezetimibe  
- Low‑Density Lipoprotein Cholesterol (LDL‑C)  
- Antithrombotic Therapy  
- Diabetes Management (Type 2 Diabetes)  
- Preventive Foot Care  
- Saphenous Vein Assessment  
- Multidisciplinary Team Evaluation  
- Guideline Class 1 Recommendation (2024 PAD Guideline)  
- Guideline Class 2 Recommendation (PCSK9, Ezetimibe)  
- Performance Measures (PM‑1 to PM‑6)  
- Quality Measures (QM‑3 to QM‑8)  
- American College of Cardiology (ACC)  
- American Heart Association (AHA)  
- Electronic Health Record (EHR)  
- Chronic Limb‑Threatening Ischemia (CLTI)  
- Health Disparities in PAD  
- Peripheral Artery Disease Risk Factors (Hypertension, Diabetes, Dyslipidemia)

Page 10 Extracted Terms:
- Peripheral Artery Disease (PAD)  
- ACC/AHA Peripheral Artery Disease Measures  
- American College of Cardiology (ACC)  
- American Heart Association (AHA)  
- Cardiovascular  
- Vascular  
- Cardiovascular Angiography and Interventions  
- Interventional Cardiovascular Procedures  
- Cardiovascular and Pulmonary Rehabilitation  
- Vascular Medicine  
- Vascular Nursing  
- Vascular Surgery  
- Endovascular Surgery  
- Clinical Practice Guidelines  
- Guideline Science and Methodology  
- Scientific Statements  
- Systematic Reviews  
- Performance Measures (cardiovascular performance metrics)  
- Current Procedural Terminology (CPT) codes (used in cardiovascular coding)  
- Quality & Health IT (related to cardiovascular care)  
- Clinical Policy and Guidelines (cardiovascular)  

These terms capture the key concepts related to heart disease and cardiovascular care that appear in the provided text.

Page 11 Extracted Terms:
- Peripheral artery disease  
- Peripheral vascular disease  
- Critical limb ischemia  
- Hypertension (high blood pressure)  
- Blood‑pressure control  
- Intensive blood‑pressure control  
- Heart failure  
- Acute coronary syndrome  
- Coronary artery disease  
- Major adverse cardiovascular events (MACE)  
- Cardiovascular outcomes  
- Vascular events  
- Lower‑extremity amputation  
- Foot ulcer / diabetic foot ulcer  
- Revascularization  
- Beta‑blockers  
- Angiotensin‑converting enzyme inhibitors (ACEi)  
- Angiotensin‑receptor blockers (ARBs)  
- Sodium‑glucose cotransporter‑2 (SGLT2) inhibitors  
- Canagliflozin (Invokana)  
- Empagliflozin  
- Dapagliflozin  
- Ertugliflozin  
- Glucagon‑like peptide‑1 (GLP‑1) receptor agonists  
- Liraglutide  
- Semaglutide  
- Exenatide  
- Dulaglutide  
- Cardiovascular‑glycemic management (e.g., GLP‑1 and SGLT2 agents)  
- Diabetes‑related cardiovascular risk  
- Clinical performance measures for cardiovascular care  
- Guideline‑based clinical practice for heart disease  

(Each line represents a distinct term or concept relevant to heart disease as derived from the provided text.)

Page 12 Extracted Terms:
Peripheral Artery Disease  
Major Adverse Limb Events  
Cardiovascular Disease  
Rivaroxaban  
Aspirin  
Warfarin  
Oral Anticoagulant Therapy  
Cholesterol  
Low‑Density Lipoprotein (LDL)  
Simvastatin  
Statin Therapy  
PCSK9 Inhibitors  
Evolocumab  
Alirocumab  
Lipoprotein(a)  
Smoking Cessation  
Tobacco Cessation  
Electronic Cigarettes  
Vaping Products  
Endovascular Revascularization  
Claudication  
Supervised Exercise  
Home‑Based Walking Exercise  
Stent Revascularization  
Angioplasty  
Infrapopliteal Balloon Angioplasty  
Critical Limb Ischemia  
Peripheral Arterial Bypass  
Revascularization  
Lifestyle Management  
Atherosclerotic Risk  
Diabetes  
Glycemic Control  
Antiplatelet Therapy  
Thromboembolic Events  
High‑Risk Conditions  
Medication Adherence  
Cardiopulmonary Impact  
Cardiovascular Events  
Mortality  
Risk Factors  
Guideline Recommendations  
Clinical Trial  
Randomized Controlled Trial  
Meta‑Analysis  
Systematic Review  
Cohort Study  
Population‑Based Study  
Health Outcomes  

Page 13 Extracted Terms:
- Peripheral artery disease (PAD)  
- Intermittent claudication  
- Endovascular revascularization  
- Percutaneous transluminal angioplasty (PTA)  
- Endovascular treatment (ET)  
- Supervised exercise therapy (SET)  
- Home‑based walking exercise  
- Treadmill training  
- Arm‑ergometer exercise  
- Resistance training  
- Functional status  
- Walking capacity / walking distance  
- Endothelial function  
- Quality of life (QOL)  
- Functional impairment  
- Clinical outcomes  
- Cardiovascular / vascular function  
- Pulmonary/renal comorbidity (e.g., renal insufficiency)  
- Prevalence of peripheral arterial disease  
- Diagnosis / detection of PAD  
- Awareness of PAD  
- Management of PAD  
- Treatment options for PAD  
- Exercise prescription for PAD  
- Leg ischemia  
- Symptomatic peripheral arterial disease  
- Atherosclerosis  
- Coronary artery disease (referenced in broader context)  
- Atherosclerotic disease risk  
- Lower extremity manifestations of PAD  
- Peripheral arterial disease epidemiology  
- Gaps in management of PAD  
- Future directions in PAD treatment  

These terms capture the key cardiovascular and peripheral arterial disease concepts discussed in the provided text.

Page 14 Extracted Terms:
- Peripheral Artery Disease (PAD)  
- Lower‑extremity peripheral arterial disease  
- Ankle‑Brachial Index (ABI)  
- Chronic limb‑threatening ischemia  
- Revascularization  
- Endovascular therapy  
- Vein bypass graft  
- Vein graft failure  
- Neointimal hyperplasia  
- Diabetic foot ulcer  
- Foot ulceration and amputation  
- Peripheral vascular disease (PVD)  
- Vascular assessment  
- Vascular surgery  
- Vascular risk  
- Cardiovascular risk factors  
- Cardiovascular morbidity  
- Cardiovascular mortality  
- Major cardiovascular events  
- Sex‑specific cardiovascular risk  
- Racial disparities in cardiovascular care  
- Socioeconomic deprivation and vascular health  
- Rural health disparities in vascular care  
- Peripheral Artery Questionnaire (PAQ)  
- Vascular quality‑of‑life questionnaire  
- PAD‑specific quality of life (PADQOL)  
- ACC/AHA Peripheral Artery Disease Measures  
- BASIL‑2 trial  
- PREVENT III study  
- PED-FOG (edifoligide prevention study)  
- PORTRAIT PAD Registry  
- REACH registry  
- Community‑based screening for PAD  
- Clinical guidelines on PAD care  
- Vascular follow‑up guidelines (Surgery & Endovascular)

Page 15 Extracted Terms:
- Peripheral Artery Disease (PAD)  
- Critical Limb Ischemia  
- Limb‑threatening Ischemia  
- Infrainguinal Bypass Graft  
- Endovascular Revascularization  
- Duplex Ultrasound Surveillance  
- Prosthetic Bypass Failure  
- Warfarin Therapy (in the context of graft patency)  
- Graft Surveillance  
- Lower Extremity Arterial Revascularization  
- Post‑Therapy Imaging  
- Appropriate Use Criteria (for vascular diagnostics)  
- Multidisciplinary Care in Vascular Disease  
- Wound Healing in Peripheral Artery Disease  
- Diabetic Foot Ulcer  
- Neuroischemic Wounds  
- Vascular Imaging  
- Peripheral Vascular Ultrasound  
- Hemodynamic Assessment (arterial ultrasound)  
- Cardiovascular Outcomes in Peripheral Disease  
- Vascular Ultrasound Screening (for PAD)  
- Vascular Guidelines for Chronic Limb‑Threatening Ischemia  
- Vascular Surveillance Protocols (duplex)  
- Atherosclerotic Vascular Disease  
- Lower Extremity Arterial Disease  

Page 16 Extracted Terms:
**Key heart‑disease related terms**

- Peripheral Artery Disease (PAD)  
- Hypertension / High Blood Pressure (HBP)  
- Blood Pressure (BP)  
- Systolic Blood Pressure (SBP)  
- Diastolic Blood Pressure (DBP)  
- Antihypertensive therapy  
- Major Adverse Cardiovascular Events (MACE)  
- Chronic Kidney Disease (CKD)  
- End‑Stage Kidney Disease (ESKD)  
- Ankle‑Brachial Index (ABI)  
- Cardiovascular (clinical) guidelines (ACC/AHA)  
- Cardiovascular risk factor  
- Vascular disease  
- BP control / BP goal (<130/<80 mm Hg)  
- BP measurement (home, office, electronic)  
- MACE risk reduction  
- Cardiovascular event prevention  
- Cardiovascular performance metrics  
- Cardiovascular outcome (MACE, CKD progression, decline in ABI)  

These terms capture the core heart‑disease concepts presented in the guideline summary.

Page 17 Extracted Terms:
**Key heart‑disease–related terms**

- Angiotensin‑converting enzyme (ACE) inhibitor  
- Angiotensin‑receptor blocker (ARB)  
- Angiotensin‑receptor‑neprilysin inhibitor (ARN)  
- Peripheral arterial disease (PAD)  
- Hypertension  
- Ankle‑brachial index (ABI)  
- Chronic limb‑threatening ischemia (CLTI)  
- Myocardial infarction (MI)  
- Stroke  
- Vascular death  
- Major adverse cardiovascular events (MACE)  
- Ramipril  
- Telmisartan  
- Cardiomyopathy  
- Heart Outcomes Prevention (HOPE) trial  
- ONTARGET (Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial)  
- Blood pressure (BP) — systolic (SBP) and diastolic (DBP)  
- End‑stage kidney disease (ESKD)  

These terms capture the core medical concepts related to cardiovascular disease and its management within the provided text.

Page 18 Extracted Terms:
- Peripheral Artery Disease (PAD)  
- Type 2 Diabetes Mellitus  
- Glucagon‑like peptide‑1 (GLP‑1) agonists  
- Sodium‑glucose cotransporter‑2 (SGLT‑2) inhibitors  
- Major Adverse Cardiovascular Events (MACE)  
- Heart Failure  
- Empagliflozin  
- Canagliflozin  
- Dapagliflozin  
- Liraglutide  
- Semaglutide  
- Limb survival  
- Amputation  
- Cardiovascular Outcomes Trial  
- Vascular disease  

Page 19 Extracted Terms:
**Key Terms Related to Heart Disease**

- Peripheral Artery Disease (PAD)  
- Symptomatic PAD  
- Chronic Limb‑Threatening Ischemia (CLTI)  
- Myocardial Infarction (MI)  
- Stroke  
- Cardiovascular death  
- Major Adverse Cardiovascular Events (MACE)  
- Major Adverse Limb Events (MALE)  
- Coronary Artery Disease (CAD)  
- Carotid disease  
- Ankle‑Brachial Index (ABI)  
- Acute Coronary Syndrome (ACS)  
- Revascularization (endovascular or surgical)  
- Endovascular limb revascularization  
- Surgical limb revascularization  
- Bypass surgery  
- Percutaneous intervention  
- Antithrombotic therapy  
- Low‑dose rivaroxaban  
- Low‑dose aspirin  
- Dual antiplatelet therapy  
- Full‑intensity anticoagulation  
- Vitamin K antagonists (VKA)  
- Direct oral anticoagulants (DOAC)  
- Bleeding risk (associated with anticoagulation)  
- COMPASS trial (cardiovascular outcomes)  
- VOYAGER trial (anticoagulation with aspirin)  

These terms capture the core concepts, conditions, treatments, and clinical trial references pertinent to heart disease described in the text.

Page 20 Extracted Terms:
- Peripheral Artery Disease (PAD)  
- High‑Intensity Statin Therapy  
- Atorvastatin (≥ 40 mg)  
- Rosuvastatin (≥ 20 mg)  
- Low‑Density Lipoprotein Cholesterol (LDL‑C)  
- Dyslipidemia  
- Cholesterol‑lowering therapy  
- Statins (hydroxymethylglutaryl‑Coenzyme A reductase inhibitors)  
- Atherosclerosis / Plaque  
- Major Adverse Cardiac Events (MACE)  
- Major Adverse Limb Events (MALE)  
- Myocardial Infarction (MI)  
- Stroke  
- Coronary Artery Disease (CAD)  
- Cardiovascular Death  
- Risk reduction of cardiovascular events  
- Heart Protection Study (HPS)  

These terms capture the key heart‑disease concepts discussed in the guideline text.

Page 21 Extracted Terms:
- Peripheral Artery Disease (PAD)  
- Major Adverse Limb Events (MALE)  
- Major Adverse Cardiovascular Events (MACE)  
- Tobacco use  
- Smoking cessation  
- Electronic Nicotine Delivery Systems (ENDS)  
- Second‑hand smoke  
- Varenicline (treatment)  
- Bupropion (treatment)  
- Nicotine Replacement Therapy (NRT)  
- Cessation counseling  
- Lower‑extremity peripheral artery disease  
- ACC/AHA guidelines for PAD  
- ACC/AHA/AACVPR/APMA/ABC/SCAI/SVM/SVN/SVS/SIR/VESS Guideline  
- American College of Cardiology (ACC)  
- American Heart Association (AHA)  
- American Association of Cardiovascular and Pulmonary Rehabilitation (AACVPR)  
- Association of Black Cardiologists (ABC)  
- Society for Cardiovascular Angiography and Interventions (SCAI)  
- Society of Interventional Radiology (SIR)  
- Society for Vascular Medicine (SVM)  
- Society for Vascular Nursing (SVN)  
- Society for Vascular Surgery (SVS)  
- Vascular and Endovascular Surgery Society (VESS)  
- Electronic Health Record (EHR)  
- Digital health solutions  
- Group therapy models  
- Cardiovascular disease  
- Stroke (as a related outcome)

Page 22 Extracted Terms:
- Peripheral Artery Disease (PAD)  
- Chronic symptomatic PAD  
- Claudication (intermittent claudication)  
- Chronic limb‑threatening ischemia (CLTI)  
- Ischemic rest pain  
- Non‑healing ischemic ulcers  
- Gangrene  
- Unstable angina  
- Myocardial infarction (MI)  
- Decompensated heart failure  
- Uncontrolled cardiac arrhythmias  
- Severe or symptomatic valvular disease  
- Revascularization (e.g., endovascular or surgical)  
- Supervised Exercise Therapy (SET)  
- Structured Community‑Based Exercise Therapy  
- Walking performance (functional outcome)  
- Functional status (exercise tolerance)  
- Quality of Life (QOL)  
- Alternative non‑walking exercise (arm ergometry, stationary cycling)  

These terms capture the primary heart‑vascular conditions, relevant complications, and key therapeutic concepts discussed in the text.

Page 23 Extracted Terms:
**Key heart‑disease related terms extracted from the text**

- Peripheral Artery Disease (PAD)  
- Lower Extremity PAD  
- Vascular Review of Systems (vascular review)  
- Walking impairment / Claudication  
- Ischemic rest pain  
- Lower extremity non‑healing wounds  
- Exertional leg symptoms  
- Ischemic skin changes  
- Atherosclerosis  
- Coronary artery disease  
- Cerebrovascular disease  
- Polyvascular disease  
- Microvascular disease  
- Retinopathy  
- Neuropathy  
- Nephropathy  
- Chronic Kidney Disease (CKD)  
- End‑Stage Kidney Disease (ESKD)  
- Estimated Glomerular Filtration Rate (eGFR) <60 mL/min/1.73 m²  
- Diabetes Mellitus  
- Smoking / Tobacco use (including other forms of tobacco)  
- Older age (≥ 75 years)  
- Frailty  
- Mobility impairment  
- Depression  
- Risk amplifiers (≥ 1 of the above factors)  
- Clinical assessment for PAD  
- Diagnostic testing for PAD  
- Vascular examination of legs and feet  
- Vascular inspection of lower extremities  
- ACC/AHA Peripheral Artery Disease Measures (QM-1)  
- Electronic Health Record (EHR) – data source for cardiovascular assessment  
- Administrative data/claims – data source for cardiovascular measurement  
- Inpatient care setting – cardiovascular care context  
- Outpatient care setting – cardiovascular care context  

These terms capture the core cardiovascular concepts, risk factors, diagnostic elements, and quality‑measurement language present in the provided guidelines.

Page 24 Extracted Terms:
- Peripheral Artery Disease (PAD)  
- Atherosclerosis  
- Cardiovascular risk factors  
- Atherosclerotic vascular disease  
- Coronary artery disease  
- Cerebrovascular disease  
- Polyvascular disease (disease in ≥2 arterial beds)  
- Microvascular disease (retinopathy, neuropathy, nephropathy)  
- Diabetes mellitus  
- Smoking / tobacco use  
- Chronic Kidney Disease (CKD)  
- End‑Stage Kidney Disease (ESKD / dialysis dependence)  
- Estimated Glomerular Filtration Rate (eGFR)  
- Older age (≥75 years)  
- Geriatric syndromes (frailty, mobility impairment)  
- Depression (as a risk amplifier)  
- Lower‑extremity pulse examination  
- Femoral pulse  
- Popliteal pulse  
- Dorsalis pedis pulse  
- Posterior tibial pulse  
- Exertional leg symptoms  
- Lower‑extremity rest pain  
- Ischemic skin changes (wounds, ulceration)  
- Vascular examination of legs and feet  
- Clinical assessment / risk assessment  
- Risk amplifiers (clinical definitions for PAD)

Page 25 Extracted Terms:
- Peripheral artery disease (PAD)  
- Cardiovascular disease (CVD)  
- Coronary artery disease (CAD)  
- Heart failure  
- Cerebrovascular disease  
- Chronic limb‑threatening ischemia (CLTI)  
- Lower extremity revascularization  
- Tobacco use  
- Diabetes mellitus  
- Chronic kidney disease (CKD)

Page 26 Extracted Terms:
- Peripheral Artery Disease (PAD)  
- Lipid‑Lowering Therapy  
- Statin therapy  
- High‑intensity statin therapy  
- Maximum tolerated statin  
- PCSK9 inhibitors  
- Ezetimibe  
- Low‑density lipoprotein cholesterol (LDL‑C)  
- LDL‑C target ≤ 70 mg/dL  
- Major Adverse Cardiac Events (MACE)  
- Major Adverse Limb Events (MALE)  
- Myocardial infarction (MI)  
- Stroke  
- Cardiovascular death  
- Chronic limb‑threatening ischemia (CLTI)  
- Clinical measures (QM‑4)  
- Randomized controlled trial (RCT)  
- IMPROVE‑IT Trial  
- FOURIER Study  
- ODYSSEY OUTCOMES Trial  
- Hazard Ratio (HR)  
- ACC/AHA guidelines  
- ACC  
- AHA  
- AACVPR  
- APMA  
- ABC  
- SCAI  
- SIR  
- VESS  
- SVM  
- SVN  
- SVS  
- EHR (electronic health record)  

Page 27 Extracted Terms:
- Peripheral Artery Disease (PAD)  
- Lower extremity PAD  
- Peripheral vascular disease  
- Lower extremity amputation  
- Revascularization procedures (e.g., angioplasty, bypass, endovascular therapy)  
- Evidence‑based therapies  
- Statins  
- Antiplatelet agents (e.g., aspirin, clopidogrel)  
- Dual antiplatelet therapy  
- Diagnostic testing for PAD  
- Screening and referral processes  
- Atherosclerosis  
- Critical limb ischemia  
- Cardiovascular disease  
- Diabetes mellitus (risk factor)  
- Hypertension (risk factor)  
- Dyslipidemia / hyperlipidemia  
- Smoking (risk factor)  
- Obesity (risk factor)  
- Racial disparities  
- Ethnic disparities  
- Sex disparities  
- Gender‑identity disparities  
- Socioeconomic status (SES)  
- Income level  
- Educational status  
- Housing stability  
- Housing status  
- Transportation access  
- Rurality / geographic remoteness  
- Social determinants of health  
- Intersectionality (combined risk factor impact)  
- Health disparities in diagnosis, treatment, and outcomes  
- Morbidity and mortality associated with PAD  
- Access to specialized vascular care  
- Virtual or home‑based care delivery.

Page 28 Extracted Terms:
- American College of Cardiology (ACC)  
- American Heart Association (AHA)  
- Peripheral Artery Disease (PAD)  
- Chronic Limb‑Threatening Ischemia (CLTI)  
- Saphenous Vein (Great Saphenous Vein)  
- Revascularization (surgical bypass, endovascular)  
- Ultrasound Mapping  
- Surgical Bypass Surgery  
- Endovascular Therapy  
- BEST‑CLI Trial  
- Class I Clinical Recommendation  
- Level of Evidence: B‑R  
- Society for Cardiovascular Angiography and Interventions (SCAI)  
- Society of Interventional Radiology (SIR)  
- Society for Vascular Medicine (SVM)  
- Society for Vascular Nursing (SVN)  
- Society for Vascular Surgery (SVS)  
- Vascular and Endovascular Surgery Society (VESS)

Page 29 Extracted Terms:
**Key terms related to heart disease (peripheral artery disease & related care):**

- Peripheral artery disease (PAD)
- Ankle‑brachial index (ABI)
- Duplex ultrasound surveillance (DUS)
- Autogenous vein bypass graft (AVBG)
- Autogenous vein bypass graft surgery
- Lower extremity revascularization
- Infrainguinal bypass graft
- Prosthetic bypass graft
- Endovascular procedure
- Graft failure
- Stenotic lesions
- Lower extremity ischemia
- Graft patency (primary, assisted primary, secondary)
- Longitudinal follow‑up
- Clinical evaluation (pulse, foot assessment)
- Functional status
- Quality of life (QOL)
- Risk factor management
- Surveillance protocols
- Clinical recommendation
- Class 1/2a/2b recommendations
- Level of evidence (C‑EO, B‑NR, C‑LD, B‑R, C‑LD)
- Quality measure (QM‑7)
- Circ Pulm Health Outcomes (journal)
- ACC/AHA peripheral artery disease guideline
- AACVPR (American Association of Cardiovascular and Pulmonary Rehabilitation)
- AHA (American Heart Association)
- ACC (American College of Cardiology)
- APMA (American Podiatric Medical Association)
- ABC (Association of Black Cardiologists)
- SCAI (Society for Cardiovascular Angiography and Interventions)
- SVS (Society for Vascular Surgery)
- SIR (Society of Interventional Radiology)
- SVM (Society for Vascular Medicine)
- SVN (Society for Vascular Nursing)
- VESS (Vascular and Endovascular Surgery Society)
- Electronic health record (EHR)
- Administrative data / claims
- Imaging laboratory records
- Outpatient care setting
- 12‑month measurement period
- Lower extremity surveillance procedure
- ABI and arterial DUS screening interval (1–3 months, 6 months, 12 months, annual)

Page 30 Extracted Terms:
- ACC (American College of Cardiology)  
- AHA (American Heart Association)  
- Cardiac (related to heart)  
- Cardiovascular  
- Peripheral Artery Disease (PAD)  
- Chronic Limb‑Threatening Ischemia (CLTI)  
- Revascularization (endovascular or surgical)  
- Multidisciplinary Team (MDT) evaluation  
- Wound healing  
- Offloading  
- Infection management  
- Palliative care (limb)  
- Limb preservation/limb salvage  
- Amputation (most distal level)  
- Endovascular revascularization  
- Surgical revascularization  
- Wound‑healing therapies  
- Foot surgery  
- Vascular surgery  
- Orthopedics  
- Podiatry  
- Plastic surgery  
- Rehabilitation  
- Diabetes management  
- Orthotics  
- Prosthetics  
- Case conferences  
- Morbidity and mortality discussions  
- Shared decision‑making  
- Quality measure (QM‑8)  
- Class I recommendation (Class 1)  
- Level of Evidence (B‑NR, C‑EO, etc.)  
- PAD guideline (2024 ACC/AHA/AACVPR/APMA/ABC/SCAI/SVM/SVN/SVS/SIR/VESS)  
- Endovascular therapy  
- Surgical therapy  
- Multispecialty care team  

*(These terms capture the cardiovascular/heart‑related concepts, clinical processes, and guideline terminology referenced in the text.)*

Page 31 Extracted Terms:
- Peripheral Artery Disease (PAD)  
- Vascular Surgery  
- Cardiovascular Medicine  
- Interventional Cardiologist  
- American Heart Association (AHA)  
- American College of Cardiology (ACC)  
- AHA/ACC (combined AHA‑ACC entity)  
- ACC/AHA Peripheral Artery Disease Measures  
- Clinical Performance and Quality Measures for Patients With Peripheral Artery Disease  
- Society for Cardiovascular Angiography and Interventions (SCAI)  
- Society for Vascular Surgery (SVS)  
- AHA/ACC Guideline Liaison  
- Performance Measures (cardiovascular/vascular)  
- Vascular Health Institute (vascular‑medicine focus)

Page 32 Extracted Terms:
**Key heart‑disease related terms extracted from the text**

- Peripheral Artery Disease (PAD)  
- ACC/AHA Peripheral Artery Disease Measures  
- Cardiovascular Medicine  
- Interventional Cardiologist  
- Cardiovascular Surgery  
- Cardiology / Cardiac  
- Heart (as part of institution name)  
- AHA (American Heart Association)  
- NIH (National Institutes of Health)  
- Abiomed  
- Chiesi USA  
- Idorsia  
- SIR (Society for Interventional Radiology)  
- Vascular Surgery  
- Vascular (as a related medical specialty)

Page 33 Extracted Terms:
- Cardiovascular  
- Cardiovascular medicine  
- Cardiology  
- Heart  
- Heart disease  
- Peripheral artery disease (PAD)  
- Vascular  
- Vascular medicine  
- Vascular surgery  
- Cardiovascular and pulmonary rehabilitation  
- ACC (American College of Cardiology)  
- AHA (American Heart Association)

Page 34 Extracted Terms:
- Peripheral Artery Disease  
- Cardiovascular — Cardiology, Cardiovascular Research, Cardiovascular Innovations Foundation  
- Cardiac Rehabilitation  
- Cardiac Exercise Physiologist  
- Cardiologist  
- Lipid Clinic (Cardiovascular Disease Prevention)  
- Rasmussen Cardiovascular Disease Prevention Center  
- Clinical Performance and Quality Measures for Patients With Peripheral Artery Disease  
- ACC/AHA (American College of Cardiology/American Heart Association)  
- SVS (Society of Vascular Surgeons)  
- JCPM (Joint Commission on Practice‑Mediated)  
- AACVPR (American Association of Cardiovascular & Pulmonary Rehabilitation)  
- APMA (American Physical Medicine & Rehabilitation)  
- Endowed Chair in Cardiology  
- Peripheral Artery Disease Measures  
- Cardio‑vascular Innovations Foundation  
- AngioSafe  
- Kaneka Pharma America LLC  
- Elsevier (clinical research)  
- GE Healthcare (cardiovascular imaging)  
- Novartis (cardiovascular therapeutics)  
- Inari Medical (vascular interventions)  
- Pfizer (cardiovascular drugs)  
- Amgen (cardiovascular biologics)  
- Arrowhead Pharmaceuticals (cardiovascular therapeutics)  
- NHLBI (National Heart, Lung, and Blood Institute)  
- Cook Medical (vascular and cardiovascular products)

Page 35 Extracted Terms:
- ACC (American College of Cardiology)  
- AHA (American Heart Association)  
- ACC/AHA (American College of Cardiology / American Heart Association)  
- Cardiologist  
- Cardiology  
- Cardiovascular  
- Cardiovascular and Pulmonary Rehabilitation  
- Heart  
- Heart and Vascular Center  
- Peripheral Artery Disease  
- Vascular Medicine  
- Vascular Medicine Outcomes Program (VAMOS)  
- Vascular Surgery  
- Vascular Surgeon  
- National Heart, Lung, and Blood Institute (NHLBI)  
- National Lipid Association (NLA)  
- Society for Cardiovascular Angiography and Interventions (SCAI)  
- Society of Interventional Radiology (SIR)  
- Society for Vascular Medicine (SVM)  

